KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Acadia Pharmaceuticals (ACAD) Shares Outstanding (Diluted Average) (2020 - 2025)

Historic Shares Outstanding (Diluted Average) for Acadia Pharmaceuticals (ACAD) over the last 10 years, with Q3 2025 value amounting to $170.6 million.

  • Acadia Pharmaceuticals' Shares Outstanding (Diluted Average) rose 269.11% to $170.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $170.6 million, marking a year-over-year increase of 269.11%. This contributed to the annual value of $166.4 million for FY2024, which is 155.23% up from last year.
  • Per Acadia Pharmaceuticals' latest filing, its Shares Outstanding (Diluted Average) stood at $170.6 million for Q3 2025, which was up 269.11% from $168.7 million recorded in Q2 2025.
  • Over the past 5 years, Acadia Pharmaceuticals' Shares Outstanding (Diluted Average) peaked at $170.6 million during Q3 2025, and registered a low of $160421.0 during Q2 2021.
  • In the last 5 years, Acadia Pharmaceuticals' Shares Outstanding (Diluted Average) had a median value of $164.0 million in 2023 and averaged $119.5 million.
  • Per our database at Business Quant, Acadia Pharmaceuticals' Shares Outstanding (Diluted Average) surged by 10199830.87% in 2023 and then skyrocketed by 62.72% in 2025.
  • Quarter analysis of 5 years shows Acadia Pharmaceuticals' Shares Outstanding (Diluted Average) stood at $160493.0 in 2021, then surged by 100641.47% to $161.7 million in 2022, then grew by 1.32% to $163.8 million in 2023, then grew by 1.55% to $166.4 million in 2024, then grew by 2.58% to $170.6 million in 2025.
  • Its Shares Outstanding (Diluted Average) stands at $170.6 million for Q3 2025, versus $168.7 million for Q2 2025 and $167.7 million for Q1 2025.